[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Pathways Plc ADR (CMPS)

Compass Pathways Plc ADR (CMPS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,924,830
  • Shares Outstanding, K 138,477
  • Annual Sales, $ 0 K
  • Annual Income, $ -287,860 K
  • EBIT $ -182 M
  • EBITDA $ -182 M
  • 60-Month Beta 2.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 21.90

Options Overview Details

View History
  • Implied Volatility 74.39% (+3.15%)
  • Historical Volatility 65.95%
  • IV Percentile 5%
  • IV Rank 3.32%
  • IV High 232.72% on 02/10/26
  • IV Low 68.95% on 08/14/26
  • Expected Move (DTE 2) 0.81 (5.85%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 1,035
  • Volume Avg (30-Day) 4,008
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 149,161
  • Open Int (30-Day) 136,867
  • Expected Range 12.99 to 14.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.42
  • Number of Estimates 7
  • High Estimate $-0.06
  • Low Estimate $-0.91
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) -10.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.59 +29.70%
on 07/28/26
14.59 -5.86%
on 08/12/26
+1.38 (+11.21%)
since 07/17/26
3-Month
10.15 +35.32%
on 05/20/26
15.40 -10.81%
on 06/29/26
+3.66 (+36.40%)
since 05/19/26
52-Week
3.97 +245.97%
on 08/20/25
15.40 -10.81%
on 06/29/26
+9.64 (+235.82%)
since 08/19/25

Most Recent Stories

More News
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Canaccord...

CMPS : 13.85 (-0.36%)
Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today it is working with the U.S. Department of...

CMPS : 13.85 (-0.36%)
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under...

CMPS : 13.85 (-0.36%)
Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, further validating COMP360’s potential to establish a new standard of care in TRD...

CMPS : 13.85 (-0.36%)
Compass Pathways Between Phase Three Success and a Commercial Timeline Nobody Quite Believes Yet

Barchart Research What to Expect from CMPS Earnings CMPS Generated August 4, 2026 Current Price $11.80 EPS Estimate $$-0.46 Consensus Rating Strong Buy Average Move 10.06% Compass Pathways Between Phase...

CMPS : 13.85 (-0.36%)
COMPASS Pathways Reports Before Its FDA Timeline Becomes More Than a Projection

Barchart Research What to Expect from CMPS Earnings CMPS Generated July 29, 2026 Current Price $10.90 EPS Estimate $$-0.46 Consensus Rating Strong Buy Average Move 10.06% COMPASS Pathways Reports Before...

CMPS : 13.85 (-0.36%)
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

Compass Management will host a conference call at 8:00 am ET (1:00 pm UK)

CMPS : 13.85 (-0.36%)
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

HELP : 11.77 (+0.86%)
CMPS : 13.85 (-0.36%)
ATAI : 7.32 (+0.41%)
JNJ : 272.57 (+0.54%)
LLY : 1,273.38 (+3.89%)
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy

Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct...

CMPS : 13.85 (-0.36%)
Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile

New 6-month data supports COMP360’s potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable...

CMPS : 13.85 (-0.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

COMPASS Pathways plc is a mental health care company. It operates principally in New York, USA. COMPASS Pathways plc is headquartered in London, UK.

See More

Key Turning Points

3rd Resistance Point 14.97
2nd Resistance Point 14.49
1st Resistance Point 14.19
Last Price 13.85
1st Support Level 13.41
2nd Support Level 12.93
3rd Support Level 12.63

See More

52-Week High 15.40
Last Price 13.85
Fibonacci 61.8% 11.03
Fibonacci 50% 9.68
Fibonacci 38.2% 8.34
52-Week Low 3.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.